The TP53–PIK3CA contrast provides a clinically relevant and mechanistically distinct testbed: both genes are frequent drivers in BC, associated with divergent transcriptomic programs and prognostic implications across the Cancer Genome Atlas and independent cohorts. This evidence concerns the gene TP53 and breast cancer.